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Migration and Tumor Growth
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Dominik Jungen, PhD,* Etmar Bulk, PhD,* Antje Hascher, PhD,* Danielle Wittmer,*
Alessandro Marra, MD,‡ Ludger Hillejan, MD,‡ Karsten Wiebe, MD,§ Wolfgang E. Berdel, MD,*
Rainer Wiewrodt, MD,* and Carsten Muller-Tidow, MD*
Introduction: The functions of large noncoding RNAs (ncRNAs)
have remained elusive in many cases. Metastasis-Associated-in-
Lung-Adenocarcinoma-Transcript-1 (MALAT-1) is an ncRNA that
is highly expressed in several tumor types.
Methods: Overexpression and RNA interference (RNAi) ap-
proaches were used for the analysis of the biological functions of
MALAT-1 RNA. Tumor growth was studied in nude mice. For
prognostic analysis, MALAT-1 RNA was detected on paraffin-
embedded non-small cell lung cancer (NSCLC) tissue probes (n 
352) using in situ hybridization.
Results:MALAT-1 was highly expressed in several human NSCLC
cell lines. MALAT-1 expression was regulated by an endogenous
negative feedback loop. In A549 NSCLCs, RNAi-mediated suppres-
sion of MALAT-1 RNA suppressed migration and clonogenic
growth. Forced expression of MALAT-1 in NIH 3T3 cells signifi-
cantly increased migration. Upon injection into nude mice, NSCLC
xenografts with decreased MALAT-1 expression were impaired in
tumor formation and growth. In situ hybridization on paraffin-
embedded lung cancer tissue probes revealed that high MALAT-1
RNA expression in squamous cell carcinoma of the lung was
associated with a poor prognosis. On genetic level, MALAT-1
displays the strongest association with genes involved in cancer like
cellular growth, movement, proliferation, signaling, and immune
regulation.
Conclusions: These data indicate that MALAT-1 expression levels
are associated with patient survival and identify tumor-promoting
functions of MALAT-1.
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Non-small cell lung cancer (NSCLC) accounts for a largenumber of cancer-related deaths.1 Less than 20% of
patients diagnosed with NSCLC survive more than 5 years.2
Poor prognosis of early stage NSCLC is crucially linked to
the onset of tumor metastasis after initial surgery.3 The
biological mechanism of metastasis is based on the ability of
tumor cells to both enter and leave the vasculature, to settle at
peripheral organs, and to develop secondary tumors.4 This
complex multistep process is driven by the expression of
specific gene products and genetic mutations.5–7
A focus of current research is the analysis of the role of
noncoding RNAs (ncRNAs) in cancer development. Within
the human genome, a vast variety of nuclear and cytosolic
ncRNAs exist, including miRNAs (22 nt) and piRNAs
(18–30 nt), short translational-regulatory RNAs (100–200
nt), and much longer ncRNAs (up to 10,000 nt),8 all lacking
protein-coding capacity.9,10 Although ncRNAs are abundant,
only few ncRNAs have assigned specific functions.11 Tran-
scriptome analyses identified alterations in ncRNA to occur
in various malignancies.12,13 So far, the function of miRNAs
as key components of the RNA interference (RNAi) pathway,
their role as tumor suppressors, and their impact on cancero-
genesis have been demonstrated.14,15 Nevertheless, little is
known about so-called longer ncRNAs (1 kb) and their
impact on cancerogenesis regulatory processes.13 Similar to
mRNAs, long ncRNAs are also transcribed by RNA poly-
merase II. Because they lack used open reading frames, they
are supposed either to function as genetic regulators or to
modulate chromatin, depending on their localization to the
nucleus.16
Among mammals, metastasis-associated lung adeno-
carcinoma transcript 1 (MALAT-1) is an evolutionarily
highly conserved, long noncoding 8.7-kb transcript. We iden-
tified MALAT-1 by subtractive hybridization as an overex-
pressed transcript in early-stage metastasizing NSCLC.17
MALAT-1 transcript is located on chromosome 11q13,
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known for its strong impact on tumor development and
metastasis.18,19 Because MALAT-1 lacks open reading
frames of significant length and in vitro translation of
MALAT-1 did not result in protein expression, a regulatory
or a controlling function of MALAT-1 is assumed.17 Besides
its overexpression in various human carcinomas,20
MALAT-1 can also be found in normal human and mouse
tissues.16,17 Recently, MALAT-1 was also reported to be
overexpressed in placenta previa and supposed to regulate
trophoblast invasion.21
Intracellularly, MALAT-1 is specifically retained in
nuclear speckles,16 associated with the modification or stor-
age of the premRNA processing machinery22 and thus with
potential impact on gene regulation.11 3 end processing of
MALAT-1 yields a 61-nt RNA, exclusively localized to the
cytoplasm with a relatively short half-life (mascRNA,
MALAT-1-associated small cytoplasmic RNA) and a stable
nuclear retained ncRNA. Although mascRNA folds similar to
a tRNA cloverleaf secondary structure, it is recognized by the
tRNA processing machinery but not aminoacylated. Because
of tRNA mimicry, mascRNA is supposed to take part in
MALAT-1 gene regulation.11
It was the aim of the underlying study to investigate the
biological functions of MALAT-1 in lung cancer. Our results
suggest that MALAT-1 transcript induces migration in
NSCLCs and stimulates tumor growth and invasion in vivo.
In addition, we identify MALAT-1 as a prognostic marker in
squamous cell carcinoma of the lung.
MATERIALS AND METHODS
Cell Culture
A549 lung cancer23 and plat-E cells24 were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen
GmbH, Karlsruhe, Germany) at 37°C, high humidity, and 5%
CO2. Medium was supplemented with 10% fetal calf serum,
100 U/mL penicillin, and 100 g/mL streptomycin. The
human lung squamous carcinoma cell line HTB-58 was
cultured in Eagle modified essential medium supplemented
with 0.1 mM nonessential amino acids, 1 mM sodium pyru-
vate, 2 mM L-glutamine, 10% heat-inactivated fetal bovine
serum, 100 U/mL penicillin, and 100 g/mL streptomycin.
Mouse NIH 3T3 fibroblasts were maintained in DMEM
medium enriched with 10% fetal bovine serum, 2 mM L-Glu-
tamine, 100 U/mL penicillin, and 100 g/mL streptomycin.
Cell viability was evaluated by trypan blue exclusion assay.
Cloning and Transfection of a MALAT-1
Expression Vector
Long distance polymerase chain reaction (PCR) (Ex-
pand Long Range dNTPack, Roche Diagnostics GmbH,
Mannheim, Germany) was used to amplify MALAT-1 DNA
from a BAC clone (RPCIB753D15472Q; ImaGenes GmbH,
Berlin, Germany). PCR primers contained attB-sites and the
PCR product was recombined (BP clonase, Gateway technol-
ogy, Invitrogen GmbH) into pDONR222 vector.25 Finally,
MALAT-1 was shuttled (LR clonase, Gateway technology,
Invitrogen GmbH) into PINCO vector, a retroviral expression
vector with puromycin resistance26 and enhanced green flu-
orescent protein expression. Viral supernatants, supple-
mented with 5 g/ml polybrene, were collected after 24, 48,
and 72 hours. NIH 3T3 cells were transduced with PINCO
vector supernatants.
Design and Cloning of Short Hairpin RNA
Constructs
Four short hairpin RNA (shRNA) sequences (I, II, III,
and IV) of MALAT-1 (Table 1) were designed using the
DSIR Web site (Designer of Small Interfering RNA,
http://biodev.extra.cea.fr/DSIR/DSIR.html). Specificity of
the shRNA sequences was verified by BLAST search. A
nonrelated 21 nt sequence was used as a negative shRNA
control (“scrambed shRNA,” Table 1). For shRNA expres-
sion, pRNAT-H1.1/Neo (Genscript Corp company, Piscat-
away, NJ) was used. Stable transfection of the cloned construct
into A549 cell line was performed with Nanofectine reagent
(PAA Laboratories GmbH, Co¨lbe, Germany) and cells were
selected with Neomycin (G418, 1 mg/ml; Sigma-Aldrich Che-
mie GmbH,Munich, Germany). Cells were also transfected with
a “pooled” shRNA, consisting of the shRNA II, III, and IV.
MALAT-1 RNA expression levels were determined by quanti-
tative real-time reverse transcription PCR.
Quantitative mRNA Analysis
For real-time PCR analysis, RNA was isolated with Qia-
gen RNeasy Micro Kit (Qiagen, Hilden, Germany). A total of 1
g RNA from each sample was reverse-transcribed using ran-
dom hexamer primer and Moloney murine leukemia virus re-
verse transcription (M-MLV RT; Invitrogen GmbH), according
to the enzyme manufacturer’s guidelines. Negative control re-
verse transcription samples were included without addition of
M-MLV RT. SYBR-Green PCR master mix (Applied Biosys-
tems Deutschland GmbH, Darmstadt, Germany) containing 333
nM of each forward (F) and reverse (R) primer (Table 1) and 2.5
L reverse-transcribed template were transferred into a 96-well
PCR plate (ABgene Germany, Hamburg, Germany). The primer
used were as follows: human MALAT-1 (NR_002819) forward
(5-AAAGCAAGGTCTCCCCACAAG), human MALAT-1
reverse (5-GGTCTGTGCTAGATCAAAAGGCA), murine
TABLE 1. Oligonucleotides for shRNA Constructions
shRNA
Starting
Position Nucleotide Sequence
I 166 GAGTTGTGCTGCTATCTTA
TAAGATAGCAGCACAACTC
II 2087 GGAAGATAGAAACAAGATA
TATCTTGTTTCTATCTTCC
III 6427 GGCTCTTCCTTCTGTTCTA
TAGAACAGAAGGAAGAGCC
IV 8060 GAAATAACATGTTCAAGAA
TTCTTGAACATGTTATTTC
Scrambled Randomly AGATCCGTATAGTGTACCTTA
TAAGGTACACTATACGGATCT
Pooled 2087 shRNA II, III, IV
6427
8060
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MALAT-1 (NR_002847) forward (5-GTAGGTTAAGTTG
ACGGCCGTTA), and murine MALAT-1 reverse (5-ATC
TTCCCTGTTTCCAACTCATG). PCR was performed in the
Applied Biosystems 7500 Fast Real-Time PCR System
(Applied Biosystems Deutschland GmbH). Melting curve
analysis was used to monitor specificity of the PCR products.
The PCR for each sample was performed in duplicate. Neg-
ative controls were always included. GAPDH mRNA was
used as an internal control.
Immunofluorescence Microscopy
Transfected A549 cells and NIH 3T3 cells were grown
on cover slips overnight in six-well plates. After fixation in
4% paraformaldehyde at 21°C for 20 minutes, cells were
permeabilized with 0.2% Triton X-100, blocked in 10% goat
serum, and incubated with 4,6-diamidino-2-phenylindole (1:
3000; Invitrogen GmbH) and Alexa Fluor 594 phalloidin
(1:100; Invitrogen GmbH). After consecutive washing steps
with phosphate-buffered saline and distilled deionized water,
mounting with Crystal Mount Medium (Sigma-Aldrich Che-
mie GmbH) was performed. For evaluation, an Axiovert 135
microscope with ApoTome equipment for epifluorescence
(Carl Zeiss MicroImaging GmbH, Jena, Germany) was used.
Migration Assay
A total of 5  105 A549 cells (in 100 L DMEM with
5% FCS) were seeded into the upper part of a transwell
chamber (Transwell filter inserts in 6.5 mm diameter with a
pore size of 5 m; Corning Incorporated, Corning, NY),
which was precoated with 50 g/ml fibronectin for 30 min-
utes. In the lower part of the chamber, 600 L DMEM with
20% FCS was added and the assay was performed for 16
hours at 37°C and 5% CO2. Migrated cells were analyzed by
flow cytometry. All assays were performed in triplicate and
independently performed three times.
Soft Agar Colony Formation Assay
A total of 2 103 transfected A549 cells were added to
3 ml medium Iscove’s Modified Dulbecco’s Medium
(IMDM; Invitrogen GmbH)  10% FCS  0.33% BD Difco
Agar (Beckton Dickinson GmbH, Heidelberg, Germany),
seeded on 35-mm tissue culture dishes and cultured at 37°C,
high humidity, and 5% CO2. Colonies were counted after 21
days growth by two investigators (J.H. and L.H.S.).
Cell Proliferation Assay
Transfected A549 cells (DMEM) were cultured at a
density of 5  103 cells per well in a flat bottomed 96-well
plate. cellTiter 96 (Promega Corporation, Madison, WI) was
added to each well according to the manufacturer’s instruc-
tions. Cell viability was determined by measuring the absor-
bance at 490 nm using a 550 BioRad plate-reader (Bio-Rad,
Hertfordshire, UK) every 24 hours. All assays were per-
formed in triplicate and independently repeated twice. As a
blank control, 100 L DMEM was used.
Tumor Mouse Model
Mice were housed and maintained in laminar airflow
cabinets under specific pathogen-free conditions. A549 cells
were harvested from culture flasks and transferred to serum-
free PBS (PAA Laboratories GmbH). Single-cell suspensions
(2  106 in 100 L) were injected subcutaneously into the
neck, left, and right shoulder of female CD1 nude mice (9–12
weeks old) obtained from Charles-River (Charles-River Lab-
oratories, Sulzbach, Germany). Tumor size was evaluated
using a standard caliper measuring tumor length and width in
a blinded fashion and the tumor volume was calculated using
the formula: length  width2  0.52. After 31 days, animals
were killed by cervical dislocation in deep CO2 anesthesia,
primary tumors were surgically removed, tumor weight (g)
was determined, and expression levels of both human and
murine MALAT-1 in the tumors were evaluated. Moreover,
lungs, lymph nodes (axillary, inguinal), and adrenal glands
were removed, photographed, and then frozen in liquid ni-
trogen or fixed in 4% formalin and paraffin embedded. For
histological analyses, hematoxylin and eosin staining was
performed. Immunohistochemical staining was performed
using an antibody cytokeratin (monoclonal mouse anti-hu-
man cytokeratin, Clone MNF116, Isotype: IgG1, kappa,
1:300; Dako Deutschland GmbH, Hamburg, Germany). All
experimental protocols were reviewed and approved by the
Committee on Animal Experimentation.
Human NSCLC Samples for In Situ
Hybridization (ISH) and RNA Analysis
Paraffin-embedded tissue microarray probes from 352
NSCLC patients (65 9 years, 80%male, stage I-III) diagnosed
and resected in the Department of Thoracic Surgery in Oster-
cappeln (Germany) between 1998 and 2005 were hybridized
with MALAT-1 DNA probe. Clinical TNM staging (including
clinical examination, CT scans, sonography, endoscopy, MRI,
bone scan) was performed according to UICC/AJCC recom-
mendations. To determine a definite tumor stage,27,28 the post-
surgical pathological examination was applied. Only patients
with complete follow-up data and R0 resected tumors were
included in the statistical analysis (n 222; mean 65 8 years,
80% male, stage I–III). Besides, carcinoid tumors and unspeci-
fied NSCLC were excluded. According to the WHO classifica-
tion of lung tumors,29 the primary pulmonary lesion was clas-
sified as 102 squamous cell carcinomas (46%), 82
adenocarcinomas (37%), and 38 large cell carcinomas (17%).
Overall survival (OS) time was calculated from the date of
histological diagnosis to death, progressive disease, or last con-
tact, respectively (Table 2).
Digoxigenin(DIG)-labeled DNA probes complemen-
tary to MALAT-1 RNA were generated using random prime
labeling (Roche Diagnostics GmbH). For in situ hybridiza-
tion, 5-m-thick paraffin-embedded tissue microarrays were
melted, dewaxed in xylene, rehydrated with 100% ethanol
followed by 3% H2O2, and then incubated in pretreatment
buffer at 95°C for 15 minutes. ZytoFast PLUS CISH Imple-
mentation Kit HRP-DAB (ZytoVision GmbH, Bremerhaven,
Germany) was used for the detection of DIG-labeled Zyto-
Fast CISH probes. Hybridization was performed overnight at
37°C. Duplex formation of the DIG-labeled probe was visu-
alized using a primary (unmarked) anti-DIG antibody, de-
tected by a secondary polymerized enzyme-conjugated
antibody and the enzymatic reaction of DAB (3,3-diamino-
benzidine). For evaluation, the BX 51 microscope (Olympus)
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was applied, equipped with 40 and 60 dry objectives
and using 10  22 wide-field oculars. The microscope was
connected to a digital imaging system. Immunoreactivity
was interpreted and classified blindly by two investigators
(L.H.S. and T.S.) according to Tanner et al,30 where strong
expression of MALAT-1 RNA was defined when a large
gene copy cluster in 50% of carcinoma cells or numerous
separate gene copies were seen. A weaker or absent ex-
pression of MALAT-1 RNA transcript was referred to as
“weak expression.”
To identify a human lung cancer that may have low
endogenous MALAT-1 expression, we screened human
nonsmall cell lung carcinoma tissues that were fresh frozen in
the operation theater (n  10). In the described cohort of 352
NSCLC patients, fresh frozen tissue was available from a
minor percentage of patients only. Samples were randomly
selected. With the help of an expert pathologist, only sections
containing 100% tumor tissue were used for RNA extraction.
Reverse-transcriptase (RT)-PCR analysis was performed in
triplicates as described above.
Gene Expression Analyses
RNA was isolated from murine fibroblasts (NIH 3T3)
either transduced with PINCO::MALAT-1 expression vector
or with empty control vector. Technically, RNeasy Mini Kit
(QIAgen, Hilden) and FastTrack 2.0 mRNA Isolation Kit
(Invitrogen, Karlsruhe) were applied. RNA quality control
was performed, using Agilent 2100 Bioanalyzer and RNA
Labchip (Agilent Technologies, Santa Clara, CA). For gene
expression profiling, the Mouse Gene 1.0 ST array (Af-
fymetrix, Santa Clara, CA) was used. Each gene (in total n 
28853 genes) was represented by approximately n  27
probes spread across the full length of the genes. Gene chips
were prepared according to Affymetrix protocols (Af-
fymetrix). In brief, after first- and second-strand synthesis and
biotin labeling, the samples were hybridized onto the arrays
for 16 hours at 45°C, rotating at 60 rpm. After washing
(GeneChip FS-450 fluidics station; Affymetrix), the intensi-
ties were collected by scanning the arrays with GeneChip
Scanner 3000 7G (Affymetrix).
The quality of the collected raw data was first analyzed
with Affymetrix Expression Console software. After normal-
ization (robust multichip average), log2 transformation, and
annotation of the data, differential gene expression levels
between the PINCO::MALAT-1 cells and the PINCO::empty
control vector were evaluated using BRB array tools version
4.2.0 Beta 1. We identified 250 genes, which showed a
twofold up-regulation or down-regulation. Consecutively, bi-
ological functions and network affiliations of these genes
were evaluated with Ingenuity Pathways Knowledge Base
(Ingenuity Pathways Analysis 9.0–3211 (Ingenuity Systems,
http://www.ingenuity.com).
Statistical Analysis
All data were presented as means SEM if not indicated
otherwise. The mean values of two groups were compared by
Student’s t test. Differences between multiple groups were
analyzed by one-way ANOVA analysis. Survival curves were
compared with the log-rank test. Univariate Cox survival anal-
yses were performed and multivariate analyses were performed
with the Cox proportional hazards. Features considered as po-
tential explanatory factors were as follows (reference category in
italics): sex (male versus female), age (70 years versus  70
years), stage (I versus II and III), histological tumor type (squa-
mous cell carcinoma versus nonsquamous cell carcinoma), and
MALAT-1 expression (weak MALAT-1 expression versus
strong MALAT-1 expression). To analyze the prognostic value
of the potential explanatory factors for OS, a Cox proportional
hazards model was applied using a forward stepwise selection
(inclusion criteria: p value of the score test 0.05, exclusion
criterion: p value of the likelihood ratio test 0.1). p 0.05 was
considered significant for all tests. For all gene expression
analyses, Benjamini-Hochberg multiple testing correction p val-
ues were used (log[B-Hmultiple testing correction p value]). For
statistical analysis, SPSS 18 software (SPSS GmbH, Mu¨nchen,
Germany) was applied.
RESULTS
MALAT-1 Transcript in Human Lung Cancer
Previously, we identified MALAT-1 as a large ncRNA
highly expressed in early-stage metastasizing NSCLC tumors17
(Figure 1A). We now analyzed its biological functions.
MALAT-1 transcript levels were evaluated in established hu-
TABLE 2. Baseline Characteristics of the Study
Population (n  222)
Parameter n  222 %a
Ageb (yr) 65  8
Sex 178 males 80
Never smoker 46 21
Performance status
ECOG—0 27 12
ECOG—I 186 84
ECOG—II 9 4
pT
pT1 65 29
pT2 137 62
pT34 20 9
pN
pN0 140 63
pN1–3 82 37
pStage
pStage I 130 59
pStage II 54 24
pStage III 38 17
Histological tumor type
Squamous cell carcinoma 102 46
Adenocarcinoma 82 36
Large cell carcinoma 38 17
MALAT-1 transcript amplification
Strong transcript amplification 83 37
OS time, daysc 1163 (527, 1693)
a Percent of nonmissing values.
b Mean  SD.
c Median and quartiles (Q1, Q3).
ECOG, Eastern Cooperative Oncology Group; OS, overall survival.
Journal of Thoracic Oncology • Volume 6, Number 12, December 2011 Functional Role of MALAT-1 in NSCLC
Copyright © 2011 by the International Association for the Study of Lung Cancer 1987
man NSCLC cell lines (A549, HTB 58) and fresh frozen human
NSCLC tissue samples by quantitative RT-PCR analysis. For
the tested cell lines and human NSCLC probes, MALAT-1
expression levels were very high with the transcript being
detectable even earlier than the housekeeping gene human
GAPDH (Figure 1B). This finding was reproducible with dif-
ferent amplicons (data not shown). Similar expression profiles
for MALAT-1 and GAPDH were found in many other human
malignant cell lines (n  3 solid tumor cell lines [lung, cervix];
n  6 leukemia cell lines, data not shown), confirming a high,
robust MALAT-1 expression in malignancy.
MALAT-1 Expression Increases the Migratory
Potential of Mouse Fibroblast Cells
To study the biological effects of increased MALAT-1
levels in nonmalignant cells, the entire MALAT-1 DNA was
cloned and shuttled into a PINCO expression vector. Mouse
fibroblast NIH 3T3 cells were transduced either with PINCO
expression vector or with empty vector as negative control. As
expected, transduction with PINCO expression vector resulted
in high human MALAT-1 expression (Figure 2A). Interestingly,
we also detected decreased murine MALAT-1 levels after hu-
man MALAT-1 transcript was transduced into NIH 3T3 cells
(Figure 2B). The decrease of murine MALAT-1 indicated neg-
ative feedback regulation and a tight control of endogenous
levels in nontransfected cells. Functionally, MALAT-1 trans-
duction of NIH 3T3 cells increased transwell migration toward
a high serum gradient compared with cells transduced with
empty vector (p  0.001, t test; Figure 2C).
Transduction of NIH 3T3 cells with MALAT-1 vector
versus empty vector did not alter cell proliferation (MTS cell
proliferation assay; data not shown). Neither could we ob-
serve morphological differences of nuclear or cytoplasmatic
structures after counterstaining NIH 3T3 cells (transduced
with either MALAT-1 vector or empty vector) with 4,6-
diamidino-2-phenylindole and phalloidin (data not shown).
Down-Regulation of MALAT-1 Expression
Reduces Migration Potential
Because we demonstrated human MALAT-1 transcript
to increase migration potential in mouse fibroblast cell line
NIH 3T3, we next studied the biological effects of MALAT-1
down-regulation. Because of its high MALAT-1 expression
levels, the A549 cell line was selected to analyze the effects
of down-regulation. Four shRNA oligos against MALAT-1
were constructed (Table 2) and cloned into pRNAT-H1.1/
Neo vector. Next, human A549 NSCLCs were transfected
with pRNAT-H1.1/Neo vector, expressing shRNA against
MALAT-1. As a control, A549 cells were also transfected
with “scrambled” control shRNA, without effect on
MALAT-1 expression. Transfected cells were sorted for GFP
positivity by flow cytometry (data not shown).
RT-PCR analysis demonstrated decreased MALAT-1
expression after transfection of A549 cells with shRNA
expressing pRNAT-H1.1/Neo vector. Strongest down-regu-
lation was achieved when a combination of three shRNA (II,
III, and IV; Table 2) was transfected (Figure 3A). Function-
ally, migration array revealed less migration toward a serum
gradient of A549 cells either transfected with shRNA “III”
(p  0.001, t test) or “pooled” shRNA (II, III, and IV; p 
0.001, t test), compared with “scrambled” control shRNA
(Figure 3B). Similarly, soft agar colony formation assay
demonstrated fewer colonies per well after 21 days for A549
cells transfected with pooled shRNA (II, III, and IV) versus
“scrambled” control shRNA (p  0.001, t test, Figure 3C).
Similar to NIH 3T3, no morphological differences
between A549 cells transfected with “pooled” shRNA and
“scrambled” control shRNA were seen after counterstaining
with 4,6-diamidino-2-phenylindole and phalloidin (data not
shown). Also, no altered growth properties or direct prolif-
erative advantages were observed in vitro (MTS cell prolif-
eration assay; data not shown).
Down-Regulation of MALAT-1 Expression
Reduces Tumor Growth In Vivo
A549 cells transfected with either “scrambled” control
shRNA or “pooled” shRNA (II, III, IV) were subcutaneously
injected into nude mice (n  10). Tumor growth was moni-
tored by standard caliper measuring in a blinded fashion.
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FIGURE 1. MALAT-1 transcript in human lung cancer. A,
MALAT-1 transcript (8.7 kb) is located on chromosome
11q13, known for its strong impact on tumorigenesis and
metastasis. To investigate the biological effect of MALAT-1,
down-regulation was performed by four short hairpin RNA
(shRNA) sequences at four positions (shRNA oligos—red
color). A 61-nt RNA, referred to *mascRNA (*MALAT-1-asso-
ciated small cytoplasmic RNA—blue color), reaches the cyto-
plasm.11 B, According to quantitative RNA analysis, estab-
lished human NSCLC cell lines A549, HTB 58, and NSCLC
tissues (surgical resected specimens from 10 individuals) ex-
press high levels of MALAT-1 transcript if compared with hu-
man GAPDH (housekeeping gene). All columns, mean of three
independent experiments performed in triplicate; bars, SD.
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After 31 days, animals were killed for determination of tumor
weights and immunohistochemistry.
As shown in Figure 4A, tumor development was first
visible 7 days after injection. Tumors of A549 cells transfected
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transduced with MALAT-1 expression PINCO vector.
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man A549 NSCLCs reduced migration. A, After transfection
of A549 cells with shRNA (II; III; II, III, IV) against MALAT-1,
expression of MALAT-1 is decreased, as demonstrated by
reverse-transcriptase polymerase chain reaction (RT-PCR)
analysis. Most effective down-regulation is achieved, if three
shRNA (II, III, IV) are transfected at once in A549 cell. B, Sig-
nificantly reduced transwell migration of A549 cells trans-
fected with shRNA against MALAT-1 was found if either
shRNA “III” (p  0.001, t test) or “pooled” shRNA (II,III,IV;
p  0.001, t test) was used, compared with “scrambled.” C,
Soft agar colony formation assay showed less colonies per well
after 21 days growth of A549 cells transfected with three
shRNA (II, III, IV), if compared with A549 cells (p  0.001, t
test control versus II, III, IV). All columns, mean of three inde-
pendent experiments performed in triplicate; bars, SD.
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with “pooled” shRNA (II, III, IV) grew significantly slower
(volume) in comparison with tumors of A549 cells transfected
with “scrambled” control shRNA (*p 0.05, t test, Figure 4A).
In addition, tumor weight at the time of resection was also
reduced (p 0.021, t test, Figure 4B). Nevertheless, quantitative
MALAT-1 and GAPDH transcript expression in the tumors
derived from treated A549 cell line and from the untreated
control cell line did not differ (Figure 4C).
Both histological and immunohistochemical analysis
with cytokeratin antibody confirmed tumor histology of the
transplanted cell grafts (data not shown). These observations
suggest that MALAT-1 promotes tumor growth in vivo.
Actually, this mouse model was used to study tumor growth,
and although it is not an established metastasis model, we
discovered one tumor metastasis in a left axillary lymph node
of one mouse, which received A549 cells transfected with
“scrambled” control shRNA. Besides, no other metastasis
could be found on examination of the other lymph nodes
(axillary, inguinal), adrenal glands, or lungs.
Prognostic Role of MALAT-1 Expression
In situ hybridization was used to investigate MALAT-1
expression in a large cohort of paraffin-embedded tumor
tissue samples of NSCLC patients (Table 2). The MALAT-1
transcript was predominantly localized in nuclei of tumor
cells, whereas the cytoplasm did not show specific signals
(Figure 5C). In nonmalignant normal lung tissue, MALAT-1
transcript was barely detectable (Figure 5D). In total, strong
MALAT-1 transcript expression was observed in 123 (35%)
of the tested 352 NSCLC tissues (Table 2).
For clinicopathological correlations, Fisher’s exact test
revealed significant associations of strong MALAT-1 expres-
sion both with adenocarcinoma (p  0.004) and large cell
carcinoma (p  0.027). All the other variables including sex,
age, smoker, tumor size, lymph node status, tumor stage, and
squamous cell carcinoma did not show any significant asso-
ciation with strong MALAT-1 expression (data not shown).
To evaluate survival, univariate log-rank test was per-
formed independently for squamous and nonsquamous tumor
histology. For squamous cell carcinoma, strong MALAT-1
expression was shown to be associated with poor prognosis
(p  0.012; log-rank test; Figure 5E), whereas for nonsqua-
mous cell carcinoma positive MALAT-1 expression did not
show a significant effect on prognosis (p  0.108; log-rank
test; data not shown).
The prognostic effect of MALAT-1 was also confirmed
in forward likelihood selection model using Cox proportional
hazards. NSCLC patients with squamous cell carcinoma,
whose tumors displayed a strong hybridization signal,
showed a worse outcome (OS hazard ratio 1.78; 95% CI
1.084–2.922; p  0.026). Stage was the second explanatory
factor. In contrast, in NSCLC patients with nonsquamous cell
carcinoma, histology stage and age showed a prognostic
impact on OS but not MALAT-1 expression (Table 3).
Gene Expression Analyses
The results of the gene expression analysis of 250 selected
genes were categorized into three “Top Bio Functions” groups.
Among the group “Diseases and Disorders,” the two highest
ranking items were “cancer” with 113/250 molecules (log[B-H
p value]: 1.6E-11–4.2E-04) and “inflammatory response” (n 
65; 3.9E-12–4.8E-04). Similarly, the “Molecular and Cellular
Functions” group had the most hits for “Cellular Growth and
Proliferation” (n  90; 7E-10–4.6E-04) and “Cellular move-
ment (n  75; 9.5E-14–4.8E-04). Within the third group,
“Physiological System Development and Function,” “Hemato-
logical System Development and Function” (n  76; 6.7E-09–
4.5E-04), and “Tissue Development” (n  66; 1E-08–3.5E-04)
ranked highest. These results strongly confirm the reported
functional effects of MALAT-1.
DISCUSSION
NSCLC ranks among the most common and lethal
malignant diseases.1 Poor prognosis of early stage NSCLC is
crucially linked to the onset of tumor metastasis.3 The pro-
cesses inducing and stimulating metastasis are complex and
still not well understood. In early-stage NSCLC that subse-
quently metastasized, we found the long noncoding RNA
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FIGURE 4. MALAT-1 gene knockdown suppresses tumor
growth and metastasis in nude mice. A, A549 cells trans-
fected with either scrambled control or pooled shRNA (II, III,
IV) were injected subcutaneously into nude mice (n  10) at
three locations each. After 31 days, animals were killed for
determination of tumor weights and immunohistochemistry.
Injected cells transfected with shRNA against MALAT-1 dem-
onstrated reduced tumor growth (volume) when compared
with scrambled-transfected cells (*p  0.05). B, According to
tumor volume, tumor weight was significantly less in the
“pooled” shRNA group compared with the “scrambled”
shRNA group (p  0.021). C, On day 31, murine MALAT-1
(mMALAT-1), human MALAT-1 (hMALAT-1), murine GAPDH
(mGAPDH), and human GAPDH (hGAPDH) gene expression,
respectively, were evaluated using RT-PCR. In all test sets, no
difference between both tumor types (A 549 scrambled
shRNA versus A 549 pooled shRNA) were found.
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(ncRNA) MALAT-1 at chromosome 11q13 to be overex-
pressed with potential impact on metastasis.17 ncRNAs ac-
count for approximately the 1.5% of the transcriptional out-
put of mammalian genomes.31 Besides MALAT-1, other
ncRNAs have also been described to be associated with
tumorigenesis and patient prognosis (e.g., HULC in hepato-
cellular carcinoma32). MALAT-1 is predominantly localized
in nuclear speckles.16,33 By 3 end processing, a 61-nt RNA is
generated, which is transferred to the cytoplasm. This small
RNA is called mascRNA (MALAT-1-associated small cyto-
plasmic RNA). Compared with nuclear MALAT-1 ncRNA,
mascRNA is less stable. Because of its tRNA-like cloverleaf
secondary structure and the fact that mascRNA cannot be
aminoacylated imply an interfering effect on the tRNA pro-
cessing machinery, possibly due to tRNA mimicry. It was
also postulated that the mascRNA might regulate MALAT-1
levels.11 In line with this hypothesis, our analyses in NIH 3T3
cells and NSCLC cell lines suggest that endogenous
MALAT-1 levels are tightly regulated and that an effective
feedback loop exists. These findings suggest that MALAT-1
plays an important functional role. Recently, one study dem-
onstrated MALAT-1 to be negatively related with the dephos-
phorylated pool of serine/arginine splicing factors and thus to
influence alternative splicing.33
In this study, we identified MALAT-1 as a strong
regulator for NSCLC migration and invasion in vitro. The
proliferative activity was not affected in vitro. In contrast,
significantly impaired tumor growth was observed in vivo.
This might indicate that the invasive phenotype associated
with MALAT-1 expression might lead to faster tumor growth
in vivo, while cell cycle regulation of individual tumor cells
is not affected. Similarly, apoptosis was not affected by
MALAT-1 suppression and at least a suppression of the RNA
level by 75% was not sufficient to induce cell death.
Of great interest, gene expression analysis using the
Affimetrix Gene Chip technology of the full length of 28853
mouse genes strongly confirmed the observed functional
FIGURE 5. Prognostic role of MALAT-1 expression evaluated
by chromogenic in situ hybridization. To evaluate the sensitivity
of the ISH probe, hybridization was first tested in A549 cells. A,
Strong hybridization signal of MALAT-1 RNA after transfection
of A549 cells with “scrambled” control shRNA (pRNAT-H1.1/
Neo vector). If A549 cells were transfected with “scrambled”
control shRNA (pRNAT-H1.1/Neo vector), a strong amplifica-
tion signal was detected. B, After transfection of “pooled”
shRNA, MALAT-1 amplification signal was weak, indicating
gene knock-down. C, Strong MALAT-1 transcript hybridization
signals were observed in 123 (35%) of the tested 352 NSCLC
tissues. Representative MALAT-1 staining is shown for squa-
mous cell carcinoma (blue, hematoxylin counterstaining of nu-
clei). D, In contrast to NSCLC tissues, nonmalignant lung tissue
showed a weak amplification signal of MALAT-1 RNA. E, Ka-
plan-Meier curves were used to determine the survival proba-
bility, and the log-rank test was used to compare the survival
curves between patients with and without MALAT-1 hybridiza-
tion signals. Blue indicates weak expression of MALAT-1 tran-
script and the red line stands for positive expression. For pul-
monary squamous cell carcinoma, positive MALAT-1 expression
indicated poor prognosis (p  0.012; log-rank test).
TABLE 3. OS: Explanatory Prognostic Factors for OS
Accepted in the Likelihood Forward Selection Model
OS
Explanatory
Factorsa
Squamous Cell
Carcinoma
Nonsquamous Cell
Carcinoma
HRb 95% CI pc HRb 95% CI pc
P staged 0.016 0.001
P stage II 1.72 1.00–2.98 2.10 1.24–3.58
P stage III 2.45 1.30–4.62 3.60 1.95–4.66
MALAT-1 expressione 1.78 1.08–2.92 0.026 —f
Age 70 yg —f 1.84 1.11–3.07 0.024
a Other factors not accepted by Cox regression model: sex (male 	reference
 vs.
female) and smoking status (smoker and ex-smoker 	reference
 vs. nonsmoker).
b HR 1 suggests improved survival.
c p value according to the likelihood ratio test.
d Pathological TNM tumor stage, categorized as stages I, II, and III, respectively.
P stage I is reference category.
e Expression corresponds to the intensity of ISH hybridization signal, categorized as
weak (reference) vs. moderate/strong.
f Not accepted from forward selection model.
g Age was categorized as 70 yr (reference) vs. 70 yr.
OS, overall survival; HR, hazard ratio; CI, confidence interval.
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effects of MALAT-1 in vitro and in vivo. Analyzing network
affiliations of differentially expressed genes upon MALAT-1
up-regulation with Ingenuity Pathways Knowledge Base,
MALAT-1 up-regulation is mostly associated with alterations
of the signaling pathways of “cancer,” “inflammatory re-
sponse,” “Cellular Growth and Proliferation,” “Cellular
movement,” “Hematological System Development and Func-
tion,” and “Tissue Development.”
Although the applied mouse model is not an established
metastasis model, we discovered one lymph node metastasis
in one mouse, transplanted with A549 cells transfected with
“scrambled” control shRNA. This finding might therefore
indicate increased metastasis development of tumors with
high MALAT-1 expression. The prognostic role of MALAT-1
was further corroborated in this study by in situ hybridization of
a large collection of primary NSCLC tumors. Importantly,
MALAT-1 was expressed across all tumor stages and subtypes.
High MALAT-1 levels were found for squamous cell carcino-
mas and indicated decreased survival in patients with entirely
resected NSCLC. The in situ hybridization results did not show
(as in the real-time PCR study) that especially high expression
levels of MALAT-1 also predicted survival in adenocarcinoma.
However, in situ hybridization is much less sensitive and quan-
titative than real-time PCR. Nonetheless, this study along with
previous results provides evidence that high MALAT-1 expres-
sion in NSCLC indicates a poor prognosis in patients suffering
from squamous cell carcinoma of the lung. The biological
function of MALAT-1 to stimulate migration, invasion, and
tumor growth in vivo is thus in line with the clinical findings in
NSCLC patients.
In conclusion, MALAT-1 is the first large coding RNA
that regulates metastasis development in NSCLC and proba-
bly in other cancers that overexpress MALAT-1. These
results indicate that MALAT-1 might be an important bio-
marker and a novel therapeutic target.
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